Correlation Engine 2.0
Clear Search sequence regions

  • ghana (1)
  • health personnel (1)
  • humans (1)
  • infant (1)
  • infant newborn (1)
  • kenya (1)
  • live (11)
  • low (2)
  • malawi (1)
  • peru (1)
  • public health (1)
  • rotavirus (6)
  • rotavirus vaccines (18)
  • vaccines (1)
  • Sizes of these terms reflect their relevance to your search.

    Live oral rotavirus vaccines (LORVs) have significantly reduced rotavirus hospitalizations and deaths worldwide. However, LORVs are less effective in low- and middle-income countries (LMICs). Next-generation rotavirus vaccines (NGRVs) may be more effective but require administration by injection or a neonatal oral dose, adding operational complexity. Healthcare providers (HPs) were interviewed to assess rotavirus vaccine preferences and identify delivery issues as part of an NGRV value proposition. Determine HP vaccine preferences about delivering LORVs compared to injectable (iNGRV) and neonatal oral (oNGRV) NGRVs. 64 HPs from Ghana, Kenya, Malawi, Peru, and Senegal were interviewed following a mixed-method guide centered on three vaccine comparisons: LORV vs. iNGRV; LORV vs. oNGRV; oNGRV vs. iNGRV. HPs reviewed attributes for each vaccine in the comparisons, then indicated and explained their preference. Additional questions elicited views about co-administering iNGRV+LORV for greater public health impact, a possible iNGRV-DTP-containing combination vaccine, and delivering neonatal doses. Almost all HPs preferred oral vaccine options over iNGRV, with many emphasizing an aversion to additional injections. Despite this strong preference, HPs described challenges delivering oral doses. Preferences for LORV vs. oNGRV were split, marked by disparate views on rotavirus disease epidemiology and the safety, need, and feasibility of delivering neonatal vaccines. Although overwhelmingly enthusiastic about an iNGRV-DTP-containing combination option, several HPs had concerns. HP views were divided on the feasibility of co-administering iNGRV+LORV, citing challenges around logistics and caregiver sensitization. Our findings provide valuable insights on delivering NGRVs in routine immunization. Despite opposition to injectables, openness to co-administering LORV+iNGRV to improve efficacy suggests future HP support of iNGRV if adequately informed of its advantages. Rationales for LORV vs. oNGRV underscore needs for training on rotavirus epidemiology and stronger service integration. Expressed challenges delivering existing LORVs merit further examination and indicate need for improved delivery.


    Jessica Mooney, Jessica Price, Carolyn Bain, John Tanko Bawa, Nikki Gurley, Amresh Kumar, Guwani Liyanage, Rouden Esau Mkisi, Chris Odero, Karim Seck, Evan Simpson, William P Hausdorff. Healthcare provider perspectives on delivering next generation rotavirus vaccines in five low-to-middle-income countries. PloS one. 2022;17(6):e0270369

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 35737718

    View Full Text